JCI Analysts Lead, Options Follow — Shorts Caught Offside
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

Six Wall Street firms raised price targets on JCI after its Q1 earnings beat. Now options traders are swinging bullish. Short sellers are adding exposure — but the borrow market tells a different story.
Analyst Upgrades Set the Tone
The May 7 target hikes were broad and emphatic. UBS lifted its target to $170 from $160. Wells Fargo moved to $160 from $145. RBC Capital made the biggest relative move, jumping to $154 from $139. Barclays, Citigroup, and Mizuho all followed with raises of their own.
The mean analyst price target now sits at $151.19. JCI closed Thursday at $145.03. That implies roughly 4% upside to the consensus — modest, but the direction is clear. Two firms also initiated coverage in April: Evercore ISI at $155 (In-Line) and BNP Paribas at $120 (Underperform), the lone dissenting voice.
Wellington Management added over 5 million shares in Q1. That's the biggest institutional move in the top-15 holder list by a wide margin. BlackRock added 1.07 million shares through April. Invesco added 587,000. The institutional flow aligns with the analyst direction.
Options Traders Turn Bullish
The put-call ratio dropped to 0.84 on May 14. The 20-day average is 0.98. That's a move of 2.0 standard deviations below the mean — the most bullish options positioning JCI has seen in recent weeks.
The shift is notable given the stock's Q1 earnings reaction. Shares fell 3.8% on May 6 when results were reported. The subsequent analyst upgrades reversed that quickly. JCI is now up 4.2% over the past week and 0.9% on Thursday alone.
Short Interest Rise Doesn't Signal Conviction
Short interest climbed 14.1% over the past week to 1.40% of free float. That sounds large in percentage-change terms. In absolute terms, it's not. At 1.4% of float, short positioning in JCI is light.
The borrow market confirms this. Cost to borrow dropped 53% over the past week to 0.20% annually — near the floor. Availability is extremely loose. The ORTEX short score sits at 29.9 out of 100, well below any level that would suggest meaningful short-side pressure.
The short interest rise is more likely residual hedging than a directional short thesis. Nothing in the lending data supports a squeeze narrative.
Data Summary
- Price: $145.03, +4.2% past week
- SI % of free float: 1.40% (up 14.1% in one week — but low in absolute terms)
- Cost to borrow: 0.20% (down 53% week-on-week)
- Put-call ratio: 0.84, –2.0 standard deviations below 20-day mean
- Analyst consensus target: $151.19 — six firms raised targets post-earnings
- Next earnings: June 1
Against its peers
Shares moved +4.2% over the past week against a median of -1.5% for its closest peers.
Stocks in this article
See the live data behind this article on ORTEX.
Open JCI on ORTEX →How this article was generated
- Generated
- 15 May 2026, 06:27
- Data as of
- 15 May 2026, 06:21
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signals
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.